Eli Lilly Announces $1.8 Billion Investment to Boost Drug Production in Ireland
Summary: Eli Lilly is investing $1.8 billion to expand its pharmaceutical production capabilities in Ireland, focusing on its Alzheimer’s treatment and weight-loss drugs. The move includes a significant boost to its Limerick and Kinsale facilities.
The investment will see $1 billion allocated to enhance the Limerick site, which will produce active ingredients for Eli Lilly’s Alzheimer’s drug Kisunla, recently approved by the U.S. Food and Drug Administration. This expansion follows a similar $1 billion investment made in March 2023.
Additionally, Eli Lilly is investing $800 million in its Kinsale facility to increase production of its new diabetes and obesity treatments, which began manufacturing last year.
Since 2020, Eli Lilly has committed over $20 billion to manufacturing investments across the U.S. and Europe. The company’s shares have risen approximately 60% in 2024, reflecting strong investor confidence.